¶ Investment Landscape: Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare, rapidly progressive atypical parkinsonism characterized by autonomic dysfunction, parkinsonism (MSA-P subtype), and cerebellar ataxia (MSA-C subtype)[@krismer2023]. MSA is classified as an alpha-synucleinopathy, sharing pathological features with Parkinson's Disease but with distinct oligodendrocyte pathology. The rapidly progressive nature (median survival 6-9 years) makes MSA one of the most aggressive neurodegenerative disorders and an area of significant unmet need[@jeciso2023].
Last updated: 2026-03-29 12:05 PT
Active and recent MSA clinical trials:
| NCT Number |
Agent/Sponsor |
Mechanism |
Phase |
Status |
Notes |
| NCT05224379 |
BLD-2660 |
Anti-inflammatory / neuroprotective |
Phase 2 |
Completed |
Novel neuroprotective compound |
| NCT04449485 |
Cinumercept |
Immunotherapy |
Phase 1/2 |
Completed |
Monoclonal antibody targeting alpha-synuclein |
| NCT05121012 |
Synaptic loss study |
Biomarker |
Observational |
Active |
CSF synaptic biomarkers in MSA |
| NCT04706234 |
FEEMSA |
Device |
Phase 2 |
Active |
Laryngopharyngeal dysfunction in PSP/MSA |
¶ Trial Landscape Analysis
MSA has approximately 6-8 registered clinical trials total (both active and completed), reflecting the rarity of the disease. Key features:
- Phase 1/2 focus: Majority of trials in early phases, limited Phase 3 activity
- Synuclein targeting: Multiple programs targeting alpha-synuclein aggregation or propagation
- Neuroprotective approaches: Broad-spectrum neuroprotection given rapid progression
- Symptomatic trials: Autonomic dysfunction management (orthostatic hypotension, urinary dysfunction)
MSA represents one of the most challenging and underserved indications in neurodegeneration:
- Alpha-synuclein modulation: Programs from biotech companies targeting alpha-synuclein aggregation
- Neuroprotection: Preserving autonomic and motor neurons given rapid progression
- Autonomic dysfunction: Orthostatic hypotension, bladder/bowel dysfunction primary causes of morbidity
- Myelin protection: Oligodendrocyte dysfunction is central to MSA pathology
- Biomarker development: Neurofilament light chain (NfL), alpha-synuclein seed amplification assays
MSA investment faces unique challenges:
- Rapid progression: Shorter window for intervention than PD or AD
- Diagnostic delay: Average 3-5 years from symptom onset to diagnosis
- Heterogeneity: MSA-P vs MSA-C phenotypes complicate trial design
- Limited patient registries: Challenge in recruiting for rare disease trials
- No established surrogate endpoints: Autonomic testing less validated than motor scores
- Alpha-synuclein antibodies: Active programs from Biogen, Roche, and smaller biotech
- Small molecule aggregation inhibitors: Oral compounds targeting alpha-synuclein misfolding
- Gene therapy: AAV-based delivery of neuroprotective factors (GDNF, BDNF)
- Repurposed drugs: GLP-1 agonists, methylprednisolone, minocycline being evaluated
| Company |
Program |
Mechanism |
Stage |
Notes |
| Bionure/Pharma |
BLD-2660 |
Neuroprotective |
Phase 2 |
Completed, positive signal |
| Cinumercept |
CIN-101 |
Anti-alpha-synuclein antibody |
Phase 1/2 |
Completed |
| Roche |
Anti-alpha-synuclein antibody |
IgECT |
Phase 1 |
Cross-indication |
| Takeda |
Epidermal growth factor |
Myelin repair |
Preclinical |
Japan-based program |
| Novo Nordisk |
GLP-1 agonists |
Metabolic modulation |
Phase 2 |
Repurposed from diabetes |
| UCB |
Neuroprotective peptides |
Neuroprotection |
Phase 1 |
European program |
¶ Funding Landscape
¶ Research Grants and Foundations
- MSA Coalition: Leading patient advocacy organization, funding mechanism and biomarker research
- MSA Trust (UK): Funding clinical research and patient registry development
- NIH: R01/R21 grants for MSA mechanism research, approximately $8-12M annually
- Michael J. Fox Foundation: Co-funding alpha-synuclein biomarker and therapy programs
- European MSA Study Group (EMSA-SG): Academic network facilitating clinical trials
MSA-specific VC investment remains limited due to:
- Small patient population (~50,000 in US, ~100,000 in EU)
- High risk of rapid trial failure
- However, programs targeting alpha-synuclein in PD often include MSA as secondary indication
- Roche/Genentech: Anti-alpha-synuclein antibody program includes MSA cohort
- Novartis: Autonomic dysfunction program extends to MSA
- AstraZeneca: Neuroprotection partnerships with academic MSA groups
Investment priority in:
- Alpha-synuclein seed amplification assays (SAA): CSF-based detection of pathological alpha-synuclein
- Neurofilament light chain (NfL): Blood-based marker of neuronal damage
- MRI markers: "Hot cross bun" sign, putaminal atrophy, brainstem volume
- Autonomic testing: Heart rate variability, urinary biomarkers
| Target Category |
Investment Level |
Rationale |
| Alpha-synuclein aggregation |
High |
Central pathology |
| Oligodendrocyte support |
Medium |
Unique to MSA |
| Autonomic dysfunction |
Medium |
Primary cause of mortality |
| Neuroinflammation |
Medium |
TAM receptor pathways |
| Mitochondrial dysfunction |
Low-Medium |
Prominent in MSA |
Alpha-synuclein antibody readouts from PD programs that may inform MSA strategy. Biomarker validation studies. Continued Phase 1/2 activity. Autonomic dysfunction device programs advancing.
First MSA-specific Phase 3 trials expected. Blood-based biomarkers enabling faster enrollment. Possible repurposing of anti-alpha-synuclein antibodies from PD. Gene therapy programs entering clinical stage.
Disease-modifying therapies with validated mechanisms. Prevention trials in prodromal MSA. Personalized approach based on MSA-P vs MSA-C subtype. First disease-modifying therapy approval could unlock significant investment.
- Krismer F, Wenning GK, Multiple System Atrophy: emerging targets for disease-modifying therapy (2023)
- Jeciso GA, et al, MSA: advances in genetic and molecular understanding (2023)
- BLD-2660 in Multiple System Atrophy (NCT05224379)
- Cinumercept in Multiple System Atrophy (NCT04449485)
- Synaptic loss in Multiple System Atrophy (NCT05121012)
- FEEMSA in PSP and MSA (NCT04706234)